A new 10-year regional study reveals that adults living with both HIV and hepatitis B virus across the Asia-Pacific face ...

Table 3. Summary of case series and cohort studies describing response of HIV-1/2 dual-infected patients on ART in the HAART era. Individual case reports excluded, but are discussed in the main text.

Using participant skin cells reprogrammed into neurons, Weill Cornell Medicine researchers have identified genetic signatures ...

The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...

At the cellular level, HIV-1 transmission involves a highly coordinated process whereby the virus binds to CD4 receptors and one of two coreceptors—CCR5 (R5) or CXCR4 (X4)—on host immune cells, ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

A Prescription Drug User Fee Act target date of April 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir ...

In patients with HIV infection on rifampicin TB therapy, twice-daily bictegravir/emtricitabine/tenofovir alafenamide results ...

BEAVERTON, OR, UNITED STATES, January 13, 2026 /EINPresswire.com/ -- Sedia Biosciences Corporation, a leading developer ...